Asset Details
Do you wish to reserve the book?
Late-Onset Neutropenia in Patients Treated with Rituximab for Non-Hodgkin's Lymphoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Late-Onset Neutropenia in Patients Treated with Rituximab for Non-Hodgkin's Lymphoma
Do you wish to request the book?
Late-Onset Neutropenia in Patients Treated with Rituximab for Non-Hodgkin's Lymphoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Late-Onset Neutropenia in Patients Treated with Rituximab for Non-Hodgkin's Lymphoma
2006
Overview
Late-onset grade 4 neutropenia occurred in 3 (5.6%) of 54 non-Hodgkin's lymphoma patients treated with rituximab between September 2001 and March 2004. Neutropenia appeared 5 to 25 weeks after administration of cytotoxic agents in combination with rituximab and recurred 4 and 17 weeks after the first onset in 2 patients. Five episodes occurred in a total of 332 cycles of rituximab therapy. Bone marrow findings at the time of late-onset neutropenia showed neutrophil maturation arrest with or without reversible myeloid dysplasia in 3 episodes and selective depletion of the myeloid series in 1 episode. Neither circulating immune complexes nor antineutrophil antibodies were detected during the 3 episodes that we evaluated. Bone marrow cells stained CD8- and CD57-. Late-onset neutropenia resolved 5 to 7 days after granulocyte colony-stimulating factor therapy was started. Further studies are needed to determine how rituximab functions and to identify appropriate countermeasures.
Publisher
Springer,Springer Nature B.V
Subject
/ Antibodies, Monoclonal - administration & dosage
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal, Murine-Derived
/ Antineoplastic Combined Chemotherapy Protocols - administration & dosage
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Biological and medical sciences
/ Female
/ Granulocyte Colony-Stimulating Factor - administration & dosage
/ Hematologic and hematopoietic diseases
/ Humans
/ Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
/ Lymphoma, Non-Hodgkin - complications
/ Lymphoma, Non-Hodgkin - drug therapy
/ Lymphoma, Non-Hodgkin - pathology
/ Male
/ Neutropenia - chemically induced
